EudraCT Number: 2021-005029-26 Sponsor Protocol Number: KF7039-01 Start Date: 2022-08-08
Sponsor Name: Grünenthal GmbH
Full Title: A randomized, double-blind, placebo-controlled, Phase III trial to evaluate the efficacy and safety of intra-articular injections of RTX-GRT7039 in adult subjects with pain associated with osteoart...
Medical condition: Moderate to severe pain associated with osteoarthritis of the knee
Disease: Version SOC Term Classification Code Term Level
21.1 100000004859 10023476 Knee osteoarthritis LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) NL (Ongoing) CZ (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-005026-20 Sponsor Protocol Number: mRNA-1345-P301 Start Date: 2022-08-04
Sponsor Name: ModernaTX, Inc.
Full Title: A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults ≥ 60 Years...
Medical condition: Respiratory Syncytial Virus Infection
Disease: Version SOC Term Classification Code Term Level
21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) FI (Ongoing) ES (Ongoing) PL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-002629-95 Sponsor Protocol Number: 170188 Start Date: 2022-08-02
Sponsor Name: Surgical department, Aalborg University Hospital
Full Title: Cefuroxime and Piperacillin Concentrations in the Biliary System
Medical condition: Infection in the biliary system such as cholecystitis and cholangitis both as acute infections and post-operative infections.
Disease: Version SOC Term Classification Code Term Level
20.0 100000004871 10008618 Cholecystitis chronic NOS LLT
20.0 100000004871 10008615 Cholecystitis acute NOS LLT
20.0 100000004871 10008619 Cholecystitis NOS LLT
20.0 100000004871 10004638 Bile duct stone with cholecystitis LLT
20.0 100000004871 10007004 Calculus of gallbladder with acute cholecystitis LLT
20.0 100000004871 10006995 Calculus of bile duct with acute cholecystitis LLT
20.0 100000004871 10008606 Cholangitis acute NOS LLT
20.0 100000004871 10008608 Cholangitis NOS LLT
20.0 100000004871 10008607 Cholangitis chronic NOS LLT
20.1 100000004862 10056952 Septic cholangitis LLT
23.0 100000004862 10083504 Acute obstructive suppurative cholangitis LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DK (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-005273-47 Sponsor Protocol Number: I8F-MC-GPIG Start Date: 2022-08-02
Sponsor Name: Eli Lilly and Company
Full Title: Tirzepatide Study of Renal Function in People with Overweight or Obesity and Chronic Kidney Disease with or without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease usin...
Medical condition: Obesity and Chronic Kidney disease
Disease: Version SOC Term Classification Code Term Level
20.0 10038359 - Renal and urinary disorders 10038359 Renal and urinary disorders SOC
20.0 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
Population Age: Adults Gender: Male, Female
Trial protocol: DK (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-006868-24 Sponsor Protocol Number: UMCN-AKF-21.05 Start Date: 2022-08-02
Sponsor Name: Radboud university medical centre
Full Title: Pharmacokinetics of fluconazole given orally or intravenously as prophylaxis or therapy to children and adolescents with invasive fungal infections (FOCUS)
Medical condition: Invasive fungal disease
Disease: Version SOC Term Classification Code Term Level
20.0 10021881 - Infections and infestations 10017533 Fungal infection PT
Population Age: Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-003747-22 Sponsor Protocol Number: CPHE885B12201 Start Date: 2022-08-02
Sponsor Name: Novartis Pharma AG
Full Title: A Phase 2 study of PHE885, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma
Medical condition: Adult participants with relapsed and refractory multiple myeloma who failed 3 or more different prior lines of therapy, including failing an immunomodulatory drug (IMiD), a proteasome inhibitor (PI...
Disease: Version SOC Term Classification Code Term Level
21.0 100000004864 10028228 Multiple myeloma LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) ES (Ongoing) IT (Ongoing) GR (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-006633-19 Sponsor Protocol Number: TFF-V2-001 Start Date: 2022-08-02
Sponsor Name: TFF Pharmaceuticals, Inc.
Full Title: A Phase 2, Open-Label, Randomized, Safety, Pharmacokinetic, and Efficacy Study of Voriconazole Inhalation Powder Compared to Oral Voriconazole Tablets in Subjects with Acute Invasive Pulmonary Aspe...
Medical condition: Invasive pulmonary aspergillosis
Disease: Version SOC Term Classification Code Term Level
20.1 100000004862 10022881 Invasive bronchopulmonary aspergillosis LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DK (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-003087-27 Sponsor Protocol Number: ARGX-113-2009 Start Date: 2022-07-29
Sponsor Name: argenx BV
Full Title: A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
Medical condition: Bullous Pemphigoid
Disease: Version SOC Term Classification Code Term Level
21.1 100000004858 10006567 Bullous pemphigoid LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) HU (Ongoing) ES (Ongoing) GR (Ongoing) NL (Ongoing) HR (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-000882-41 Sponsor Protocol Number: NN9535-4984 Start Date: 2022-07-27
Sponsor Name: Novo Nordisk A/S
Full Title: Investigation of once-weekly semaglutide s.c. dose-response in patients with type 2 diabetes and overweight – a participant- and investigator-blinded and sponsor open-label study
Medical condition: Diabetes Mellitus, Type 2 Overweight
Disease: Version SOC Term Classification Code Term Level
21.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
Population Age: Adults Gender: Male, Female
Trial protocol: HU (Ongoing) GR (Ongoing) PL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-006413-11 Sponsor Protocol Number: CDX0159-06 Start Date: 2022-07-27
Sponsor Name: Celldex Therapeutics
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Assess the Efficacy and Safety of CDX-0159 in Patients with Chronic Spontaneous Urticaria
Medical condition: Chronic Spontaneous Urticaria
Disease: Version SOC Term Classification Code Term Level
21.1 100000004858 10009159 Chronic urticaria LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) HU (Ongoing) ES (Ongoing) EE (Ongoing)
Trial results: (No results available)